Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present findings of three wound care related studies this Friday, October 17, at the Symposium on Advanced Wound Care in Las Vegas, Nevada.

“As a pioneer in cellular regenerative medicine dedicated to advancing the field of wound care, Osiris has developed a proprietary system for tissue processing and cryopreservation with the goal of closing chronic wounds better and faster, while also reducing overall healthcare costs,” said Lode Debrabandere, President and CEO at Osiris. “These studies demonstrate the optimal benefits of cryopreserved placental membranes, which maintain the structural and cellular integrity of the native tissue, on hard-to-close chronic wounds.”

The three presentations include:

  • A Comparison Study Between Cryopreserved and Non-cryopreserved Human Amniotic Membrane. This study demonstrates that preserving all tissue components, including the three-dimensional tissue matrix architecture, growth factors, tissue resident epithelial cells, fibroblasts and mesenchymal stem cells, is critical for tissue functionality.
  • Positive Effects of Cryopreserved Amniotic Membrane on Diabetic Wound Environment. The data indicates that using a proprietary system for tissue processing and cryopreservation is essential to ensure the highest levels of wound healing activities of placental membranes and that a combination of dehydrated amnion and chorion does not compensate for tissue cell destruction, extracellular matrix alterations, and growth factor degradation due to dehydration.
  • Use of a Cryopreserved Placental Membrane for Chronic Wounds in Patients with Autoimmune Disorders. Treating chronic wounds in patients with autoimmune diseases poses challenges to healthcare providers because of the chronic inflammatory nature of the wounds and the patients’ exposure to immunosuppressive therapies, which inhibit re-epithelialization, fibroblast response, and collagen synthesis. Complete re-epithelialization was achieved with Grafix in 87% of the patients with a mean time to closure of 7 weeks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading cellular regenerative medicine company, having developed the world’s first approved stem cell drug, remestemcel-L for graft versus host disease. Osiris’ products include Grafix® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOS®, a viable bone matrix. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology and commercial interests.

Osiris, Grafix, Cartiform, and OvationOS are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our product and product candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for marketed Biosurgery products (including Grafix, OvationOS and Cartiform) and Biosurgery products under development; our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to address medical needs; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available products, to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Additional risks and uncertainties related to the sale of our ceMSC assets and the related transactions contemplated by the Purchase Agreement with Mesoblast include typical business transactional risks, the risk of changing relationships with customers, suppliers or employees, the risk associated with the disposition of our ceMSC assets and the increased relative dependence on and importance of our other business including our Biosurgery business, the risk that we may not be able to fully benefit from the transactions through milestone payments or royalties, payment risks, including the risk associated with receipt of equity as consideration, in lieu of cash, and the risk of dependence on others to achieve results upon which milestone or royalty payments to us are conditioned. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.